The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-
weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in …

Background Continuously improving cancer-specific survival puts a growing proportion of
cancer patients at risk of major adverse cardiovascular events (MACE), but tailored tools for …

As we step into the new year with this first issue, I would like to convey warm wishes to all
our readers. May the upcoming year be a journey of collaborative exploration, marked by …

Background Venous thromboembolism (VTE) is a major preventable cause of morbidity,
disability, and mortality in subjects with cancer. A global appraisal of cancer-associated VTE …

Background Venous thromboembolism (VTE) risk is higher among patients with non–small
cell lung cancer (NSCLC) and specific subgroups, including the elderly, but little is known …

Simple Summary Cancer is associated with a high risk of developing venous
thromboembolism, which includes thrombosis in unusual areas such as the abdominal veins …

Venous thromboembolism (VTE) is a common and potentially life-threatening complication
in patients with cancer. Both cancer and its treatments increase the risk of developing VTE …

Thuny from the University Mediterranean Center of Cardio-Oncology, and colleagues. 1 The
authors point out that over the last decade or so, there has been a paradigm shift in the …

Venous thromboembolism (VTE) is a common complication in cancer patients, which is
associated with increased morbidity and mortality as well as high risk of VTE recurrence and …

The correlation between cancer and venous thromboembolism (VTE) is solid, whereas the
knowledge about cancer-related arterial thromboembolism (ATE) still needs a deeper …